Biogen (NASDAQ:BIIB) Upgraded at Barclays

Barclays upgraded shares of Biogen (NASDAQ:BIIB) to a hold rating in a research note released on Thursday morning,Zacks.com reports.

BIIB has been the topic of a number of other reports. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. HSBC reissued a “reduce” rating and set a $143.00 target price (down previously from $144.00) on shares of Biogen in a research note on Wednesday, December 10th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Biogen in a research report on Monday, February 9th. Oppenheimer boosted their price target on shares of Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, January 30th. Finally, TD Cowen raised their price objective on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Twelve research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Biogen presently has an average rating of “Hold” and a consensus target price of $205.04.

Biogen Stock Down 0.0%

Shares of BIIB opened at $192.03 on Thursday. Biogen has a 12-month low of $110.04 and a 12-month high of $202.41. The firm has a market cap of $28.18 billion, a P/E ratio of 21.80, a price-to-earnings-growth ratio of 1.52 and a beta of 0.16. The company’s 50-day moving average price is $180.02 and its 200 day moving average price is $161.29. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s revenue was down 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts forecast that Biogen will post 15.83 earnings per share for the current year.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. grew its position in Biogen by 9.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,170,907 shares of the biotechnology company’s stock worth $206,068,000 after purchasing an additional 103,425 shares during the last quarter. Compound Planning Inc. purchased a new position in shares of Biogen in the 4th quarter valued at about $577,000. Axxcess Wealth Management LLC purchased a new position in Biogen in the fourth quarter valued at about $401,000. Corient Private Wealth LLC increased its stake in Biogen by 32.9% in the 4th quarter. Corient Private Wealth LLC now owns 46,318 shares of the biotechnology company’s stock valued at $8,152,000 after purchasing an additional 11,456 shares in the last quarter. Finally, Strive Financial Group LLC acquired a new position in shares of Biogen during the 4th quarter worth $35,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: BIIB091 MS trial reaches completion — Phase 2 readout setup provides a near-term pipeline catalyst that could materially affect investor sentiment if results are favorable. Biogen’s BIIB091 MS Trial Reaches Completion
• Positive Sentiment: New Board chair Maria C. Freire appointed — her experience in biomedical research, drug development and public–private partnerships could refocus partnerships and capital allocation, which investors may view as constructive for strategy and M&A/partnering optionality. New Biogen Chair Freire May Recast Partnerships And Capital Priorities
• Positive Sentiment: Analyst / media coverage highlights improved valuation and strong recent performance — articles noting Biogen as a value / turnaround candidate and highlighting recent gains can attract investors hunting discounted quality names. This supports momentum in the stock. Assessing Biogen (BIIB) Valuation
• Positive Sentiment: Broader ALS therapeutics market growth — a market-research report projects strong CAGR for ALS therapeutics, which is relevant because Biogen has neuro/ALS programs (supporting longer-term revenue upside if clinical progress continues). Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share
• Neutral Sentiment: Macro/guidance context and value-stock debate — a piece on “value stocks walking a fine line” highlights valuation risks vs. margin of safety; useful context but not BIIB-specific catalyst. 3 Value Stocks Walking a Fine Line
• Neutral Sentiment: Short-interest data appears noisy/invalid — reported short-interest entries show zero/NaN values and thus offer no reliable signal about positioning or squeeze risk. (Treat with caution.)
• Negative Sentiment: New Alzheimer’s startup Korsana raises $175M — fresh venture capital backing for an Alzheimer’s program (originating at Paragon) increases competition in the amyloid/Alzheimer’s R&D landscape; could pressure long-term franchise assumptions depending on Korsana’s program profile and trial outcomes. An Alzheimer’s startup emerges with $175M in venture backing

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.